OSSTEC Secures $3M to Transform Bone Healing and Joint Replacement for Osteoarthritis Patients

OSSTEC is thrilled to announce a significant milestone in our journey to revolutionize joint replacement care with the successful raise of $3,000,000 in funding. Osteoarthritis affects a staggering 33% of the population, and the current standard of care—joint replacement—results in approximately 1.3 million knee replacements globally every year. Alarmingly, nearly 450,000 of these procedures are performed in young patients who face a heightened risk of failure and the need for revision surgery due to the limitations of conventional implants. These challenges have long translated to poorer outcomes and increased hesitancy among surgeons when considering treatment for younger patients. In response to this critical need, OSSTEC has developed an innovative additive manufacturing bone healing technology that is currently being applied in partial knee implants. Our breakthrough technology stimulates long-term bone growth, directly addressing common causes of implant failure such as loosening and progressive bone loss, thereby offering renewed hope for patients and a promising alternative for surgeons. The newly raised capital will be instrumental in further advancing our research and development efforts, enhancing clinical trials, and scaling production capabilities to meet the growing demand for improved orthopedic solutions. With this funding, OSSTEC is poised to accelerate the introduction of our technology into the healthcare market, ensuring that patients remain active, pain-free, and enjoy an extended quality of life. We remain committed to transforming the landscape of joint replacement, ultimately reducing the long-term complications associated with current treatments and providing a much-needed solution for a significant global health challenge.